Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKS●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$40.80
$0.65(1.62%)
U.S. Market opens in 12h 48m

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap6.8B
P/E Ratio100.55
EPS (TTM)$0.95
ROE0.04%
Fundamental Analysis

AI Price Forecasts

1 Month$50.07
3 Months$61.89
1 Year Target$43.98

ALKS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Alkermes plc (NASDAQ: ALKS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Alkermes plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALKS on the NASDAQ shows an RSI of 28.28, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $43.98 for the NASDAQ listing.

Key metrics behind Alkermes plc's NASDAQ-traded stock include a P/E ratio of 100.55 and a market capitalization of 6.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALKS on the NASDAQ.

Price Performance (NASDAQ: ALKS)

1-Day Change
1.62%
5-Day Change
-4.11%
1-Month Change
-13.94%
3-Month Change
-22.33%
6-Month Change
38.82%
Year-to-Date (YTD) Change
45.82%
1-Year Change
40.50%
3-Year Change
45.66%
5-Year Change
32.00%
All-Time (Max) Change
641.82%

Contact Information

http://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, DU, D04 C5Y6

Company Facts

20,500 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions